• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High immunoproteasome and low constitutive proteasome subunit levels correlate with sensitivity to bortezomib-containing chemotherapy: update from the Children's Oncology Group AALL1231 trial.

作者信息

Roeten Margot S F, Van Meerloo Johan, Van Dijk Suzanne N, Kwidama Zinia, Jenkins Gaye, Teachey David T, Devidas Meenakshi, Loh Mignon L, Kaspers Gertjan J L, Zweegman Sonja, Jansen Gerrit, Horton Terzah M, Cloos Jacqueline

机构信息

Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam.

Texas Children's Hospital, Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine and Dan L. Duncan Cancer Center, Houston, TX.

出版信息

Haematologica. 2025 Jun 1;110(6):1379-1383. doi: 10.3324/haematol.2024.286171. Epub 2025 Jan 30.

DOI:10.3324/haematol.2024.286171
PMID:39882653
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12130773/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d17/12130773/6823af7a8c58/1101379.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d17/12130773/631161d8a6c3/1101379.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d17/12130773/6823af7a8c58/1101379.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d17/12130773/631161d8a6c3/1101379.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d17/12130773/6823af7a8c58/1101379.fig2.jpg

相似文献

1
High immunoproteasome and low constitutive proteasome subunit levels correlate with sensitivity to bortezomib-containing chemotherapy: update from the Children's Oncology Group AALL1231 trial.高免疫蛋白酶体和低组成型蛋白酶体亚基水平与含硼替佐米的化疗敏感性相关：儿童肿瘤学组AALL1231试验的最新情况
Haematologica. 2025 Jun 1;110(6):1379-1383. doi: 10.3324/haematol.2024.286171. Epub 2025 Jan 30.
2
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.儿童肿瘤协作组试验 AALL1231：一项测试硼替佐米在新诊断的 T 细胞急性淋巴细胞白血病和淋巴瘤中的 III 期临床试验。
J Clin Oncol. 2022 Jul 1;40(19):2106-2118. doi: 10.1200/JCO.21.02678. Epub 2022 Mar 10.
3
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.接受含硼替佐米化疗的复发儿童急性白血病患者的蛋白酶体亚基表达分析及化疗敏感性
J Hematol Oncol. 2016 Sep 6;9(1):82. doi: 10.1186/s13045-016-0312-z.
4
Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.γ干扰素诱导的免疫蛋白酶体亚基组装上调克服了人血液学细胞系中的硼替佐米耐药性。
J Hematol Oncol. 2014 Jan 13;7:7. doi: 10.1186/1756-8722-7-7.
5
High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors.高免疫蛋白酶体活性和 sXBP1 在儿科前体 B-ALL 中预测对蛋白酶体抑制剂的敏感性。
Cells. 2021 Oct 22;10(11):2853. doi: 10.3390/cells10112853.
6
Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.新型免疫蛋白酶体抑制剂 PR-924 的抗白血病活性及其耐药机制。
Biochem Pharmacol. 2014 May 1;89(1):43-51. doi: 10.1016/j.bcp.2014.02.005. Epub 2014 Feb 16.
7
(Immuno)proteasomes as therapeutic target in acute leukemia.（免疫）蛋白酶体作为急性白血病的治疗靶点
Cancer Metastasis Rev. 2017 Dec;36(4):599-615. doi: 10.1007/s10555-017-9699-4.
8
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231.诱导结束时的微小残留病灶（MRD）和 T 细胞淋巴母细胞淋巴瘤的无事件生存（EFS）：儿童肿瘤学组试验 AALL1231。
Blood. 2024 May 16;143(20):2053-2058. doi: 10.1182/blood.2023021184.
9
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.对免疫蛋白酶体的靶向抑制是一种针对多发性骨髓瘤模型的有效策略，可克服对传统药物和非特异性蛋白酶体抑制剂的耐药性。
Blood. 2009 May 7;113(19):4667-76. doi: 10.1182/blood-2008-07-171637. Epub 2008 Dec 2.
10
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.更高的免疫与组成型蛋白酶体水平比值作为新型指标，可预测儿科急性白血病细胞对蛋白酶体抑制剂的敏感性。
Haematologica. 2013 Dec;98(12):1896-904. doi: 10.3324/haematol.2013.092411. Epub 2013 Sep 20.

本文引用的文献

1
An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia.T 细胞急性淋巴细胞白血病的临床试验及潜在治疗策略的最新进展。
Int J Mol Sci. 2023 Apr 13;24(8):7201. doi: 10.3390/ijms24087201.
2
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.儿童肿瘤协作组试验 AALL1231：一项测试硼替佐米在新诊断的 T 细胞急性淋巴细胞白血病和淋巴瘤中的 III 期临床试验。
J Clin Oncol. 2022 Jul 1;40(19):2106-2118. doi: 10.1200/JCO.21.02678. Epub 2022 Mar 10.
3
High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors.
高免疫蛋白酶体活性和 sXBP1 在儿科前体 B-ALL 中预测对蛋白酶体抑制剂的敏感性。
Cells. 2021 Oct 22;10(11):2853. doi: 10.3390/cells10112853.
4
Immunoproteasome Function in Normal and Malignant Hematopoiesis.免疫蛋白酶体在正常和恶性造血中的功能。
Cells. 2021 Jun 22;10(7):1577. doi: 10.3390/cells10071577.
5
Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.蛋白酶体抑制剂伊沙佐米对硼替佐米耐药白血病细胞和原发性急性白血病细胞的临床前评价。
Cells. 2021 Mar 17;10(3):665. doi: 10.3390/cells10030665.
6
Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group.硼替佐米再诱导化疗治疗首次复发的高危 ALL：来自儿童肿瘤协作组的报告。
Br J Haematol. 2019 Jul;186(2):274-285. doi: 10.1111/bjh.15919. Epub 2019 Apr 7.
7
Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia.儿童 T 细胞和 B 细胞急性淋巴细胞白血病的比较特征和结果。
Lancet Oncol. 2019 Mar;20(3):e142-e154. doi: 10.1016/S1470-2045(19)30031-2.
8
(Immuno)proteasomes as therapeutic target in acute leukemia.（免疫）蛋白酶体作为急性白血病的治疗靶点
Cancer Metastasis Rev. 2017 Dec;36(4):599-615. doi: 10.1007/s10555-017-9699-4.
9
The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.硼替佐米联合化疗治疗儿童复发/难治性急性淋巴细胞白血病。
Br J Haematol. 2017 Feb;176(4):629-636. doi: 10.1111/bjh.14505. Epub 2017 Jan 24.
10
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.接受含硼替佐米化疗的复发儿童急性白血病患者的蛋白酶体亚基表达分析及化疗敏感性
J Hematol Oncol. 2016 Sep 6;9(1):82. doi: 10.1186/s13045-016-0312-z.